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Background. When treating patients with advanced non-small cell lung cancer (NSCLC) with tyrosine kinase inhibi-
tors and chemotherapy, intercalated schedule with time separation between the two classes of drugs should avoid 
their mutual antagonism. In a survey of published trials, we focus on relation between eligibility criteria and effective-
ness of intercalated treatment.
Methods. Published documents were identified using major medical databases, conference proceedings and refer-
ences of published trials. Median progression-free survival (PFS) was taken as the basic parameter of treatment effi-
cacy. Correlation between characteristics of patients and median PFS was assessed through the Pearson’s correlation 
coefficient and the coefficient of determination, separately for first-line and second-line setting.
Results. The series includes 11 single-arm trials and 18 randomized phase II or phase III trials with a total of 2903 
patients. Treatment-naive patients or those in progression after first-line treatment were included in 16 and 13 trials, 
respectively. In 14 trials, only patients with non-squamous histology were eligible. Proportion of patients with non-
squamous carcinoma (in first-line setting), proportion of never-smokers (both in first- and second-line setting) and 
proportion of epidermal growth factor receptor (EGFR) mutant patients (both in first- and second-line setting) showed 
a moderate or strong correlation with median PFS. In six trials of intercalated treatment applied to treatment-naive 
EGFR–mutant patients, objective response was confirmed in 83.1% of cases and median PFS was 18.6 months.
Conclusions. Most suitable candidates for intercalated treatment are treatment-naive patients with EGFR–mutant 
tumors, as determined from biopsy or liquid biopsy. For these patients, experience with intercalated treatment is most 
promising and randomized trials with comparison to the best standard treatment are warranted. 
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Introduction 
Soon after the discovery of activating mutations 
of epidermal growth factor receptor (EGFR) and 
of their crucial role in determining sensitivity to 
tyrosine kinase inhibitors (TKIs), several trials 
confirmed the advantage of TKIs in comparison 
to chemotherapy for patients with advanced non-
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small cell lung cancer (NSCLC) with activating 
EGFR mutations.1-5 Due to higher response rate, 
longer time to progression and less toxicity, mono-
therapy with TKIs has been approved as the pre-
ferred first-line treatment for these patients. TKIs 
clearly improve short-term prognosis of patients 
with EGFR mutant lung cancer. Still, after a me-
dian interval of around one year, patients on treat-
ment with TKIs develop resistance and experience 
disease progression.6 New treatments, either as 
first-line or at progression are needed.7
After huge disappointment due to four large 
negative trials of chemotherapy alone versus 
chemotherapy combined with continuous applica-
tion of gefitinib or erlotinib8-11, the idea of combin-
ing TKIs with chemotherapy never fully recovered. 
Many research groups simply concluded that the 
two categories of drugs should not be used togeth-
er and most of current pre-clinical and clinical re-
search focuses on new drugs designed to overcome 
primary or acquired resistance to TKIs.12-14 The fact 
that the four trials were unselected regarding his-
tology and smoking status received little attention. 
For a quarter of patients in the TRIBUTE trial, the 
status of EGFR mutations was later determined: 
when treated with the combination in comparison 
to chemotherapy alone, EGFR mutant patients had 
higher response rate and a trend towards longer 
progression-free survival (PFS), but no advantage 
in overall survival (OS).15 
In spite of prevailing disappointment, some 
researchers insisted that the negative message of 
the four large trials should be accepted as new 
knowledge rather than ignored and developed 
the concept of intercalated treatment. The reason-
ing was clear: when applied concomitantly with 
chemotherapy, TKIs induce G1-phase cell-cycle 
arrest, due to which cell-cycle dependent chemo-
therapeutic agents will not be effective.16 Chemo-
refractoriness of cells harboring sensitizing-EGFR 
mutations in the presence of gefitinib was con-
firmed in vitro.17 Time separation with an interval 
of 6 days without TKIs to restore chemosensitiv-
ity of tumor cells should remove this mutual an-
tagonism, so as to benefit from the efficacy of both 
classes of drugs.18 Additional support for the con-
cept of intercalated treatment came from laborato-
ry experiments and from a clinical trial of sequen-
tial application of chemotherapy and TKI: proper 
sequence starting with cytotoxic drugs, followed 
by TKIs leads to their synergistic activity.19-23
So far, a few dozen clinical trials on intercalated 
treatment with chemotherapy and TKIs have been 
published. A recent review focused on trials with 
randomization between intercalated schedules and 
chemotherapy alone.24 While such a review is de-
finitively valuable, a reader is confused when fac-
ing a list of trials with a wide range of eligibility 
criteria, leading to diverging conclusions. This re-
view paper has a different goal. We believe that be-
fore proceeding with further clinical research, we 
should understand which patients will most likely 
benefit from intercalated treatment. Only after de-
fining the optimal target p opulation, future trials 
can be designed to compare intercalated treatment 
to the best standard treatment in those selected pa-
tients.
Methods
Selection of publications for analysis
Published papers and conference r eports on in-
tercalated therapy for NSCLC were eligible for re-
view. Intercalated treatment was defined as a treat-
ment with cytotoxic drug(s), combined with an 
EGFR-TKI during a part of a treatment cycle. Trials 
on chemotherapy combined with continuous ap-
plication of TKIs or a gap of less than 4 days, and 
trials using alternating cycles of cytotoxic drugs 
and of TKIs were not included in this review. 
Pubmed was used to search for published tri-
als on intercalated treatment for NSCLC, with 
the following descriptors and limits: NSCLC; 
chemotherapy and (erlotinib and/or gefitinib and/
or afatinib); clinical trial; 2006-2016 as the publi-
cation period; humans; English language. This 
initial search led to 686 publications. The list was 
then manually reviewed. Additional publications 
were identified using Web of Science cross-citation 
database, proceedings of major conferences dur-
ing the past 4 years (IASLC World Lung Cancer 
Conference, ASCO, ESMO, European Lung Cancer 
Conference) and the list of references in published 
trials. 
Analysis of published experience
Selected papers were analyzed, with focus on selec-
tion criteria and parameters of efficacy. Information 
on the proportion of patients with EGFR mutant tu-
mors was often incomplete or missing. If not avail-
able in the text, an estimate on the proportion of 
patients with EGFR mutant disease was made. As 
the first step, all patients with squamous histology 
were considered as EGFR wild-type (EGFR wt). In 
case of non-squamous histology, an estimate was 
based on proportion of never-smokers vs. smokers 
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and on ethnicity, using published meta-analysis on 
global pattern of EGFR mutations.25
Due to the wide spectrum of eligibility criteria 
and of comparator arms, randomized trials were 
not considered an appropriate basis for analysis of 
efficacy of the intercalated treatment. We therefore 
chose a different approach. Experience from single-
arm phase II trials and from the intercalated arm 
of randomized trials was analyzed in relation to 
histology, smoking status and EGFR mutation sta-
tus, separately for treatment-naive and pre-treated 
patients. Median PFS was taken as a conventional 
indicator of efficacy.
Statistical analysis
Statistical analysis was limited to intercalated treat-
ment, either in non-randomised trials or in the in-
tercalated arm of randomised trials. The strength of 
correlation between proportion of non-squamous 
tumors, proportion of non-smokers and proportion 
of EGFR-mutation positive cases with median PFS 
was evaluated calculating the Pearson’s correlation 
coefficient (R) and the coefficient of determination 
(R-squared; R2). Pearson’s R is a simple measure 
of the linear correlation between two variables, 
giving a value between +1 and −1, where +1 is a 
total positive correlation, 0 is the absence of cor-
relation, and −1 is a total negative correlation. The 
coefficient of determination is such that 0 ≤ R2 ≤ 1: 
although there are no specific cut-offs to define a 
moderate, or a strong correlation, a higher R2 score 
indicates a stronger association.
Correlations were graphically described by bub-
ble plots, where each bubble represents a study, 
with bubble size proportional to the number of 
patients included in each study. As all the analy-
ses were weighted by sample size of each study, 
weighted least-squares regression line was calcu-
lated and reported in each graph.
Statistical analyses were conducted using SPlus 
(S-PLUS 6.0 Professional, release 1; Insightful 
Corporation, Seattle, WA, USA). Graphs were re-
alized using SigmaPlot (Systat Software, San Jose, 
CA).
Results
Identification of publications for analysis
After the initial search through PubMed, 96 re-
ports were selected to which 4 trials found through 
conference proceedings and 6 trials identified by 
cross-citation database were added for a total of 
106 studies. A total of 29 trials were considered eli-
gible for the analysis (Figure 1). The series includes 
11 single-arm phase II trials, 16 randomized phase 
II trials and 2 phase III randomized trials, with a 
total of 2903 patients.26-54 
Eligibility criteria and treatments used 
Fourteen trials were limited to non-squamous his-
tology, while 15 included patients with any histo-
logic type of NSCLC. Sixteen trials were open only 
for treatment-naive patients, while 13 included 
those in progression after first-line treatment. The 
proportion of never-smokers was specified in all 
but two reports.
Five trials were limited to EGFR mutant disease 
and 4 to patients with EGFR wild-type or unknown 
tumors. Another 3 trials included a substantial 
proportion of EGFR mutant cases and separately 
reported the experience for this subpopulation of 
patients. Nine of the remaining 17 trials included 
information on EGFR status for some of their pa-
tients, but the proportion analyzed was usually 
low and thus inappropriate for any analysis. 
Records listed
in the PubMed search
(n = 686)
onal records iden ed
through other sources
(ASCO, ESMO, WCLC, ELCC) cross
cit on database a r duplicates
removed (n = 10)
Records (including published records and
ASCO / ESMO presenta ns)
(n = 696)
Records screened
(n = 696)
Records excluded
(n = 590)
cles (or abstracts)
assessed for eligibility
(n = 106)
Records excluded, with
reasons (n = 77):
• Con uous
treatment (n = 55)
• Sequen l
treatment (n = 7)
• Phase I trials (n = 9)
• Pulsed
administra n of
TKI (n = 3)
• Trials reported
twice (n = 3)
Studies included in the
analysis
(n = 29)
ASCO: American Society of Cli nical Oncology; ESMO: EuropeanSociety of Medical Oncology; WC LC : World Conference
on Lung Cancer; EL CC : European Lung Cancer Co nference: TK I: Ty rosine kinase inhibitor
FIGURE 1. Flow diagram on selection of publications for analysis.
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TABLE 1. Randomized trials on intercalated chemotherapy and TKIs for non-small cell lung cancer
REFERENCE TYPE OF TRIAL
# 
OF 
PTS
SELECTION OF 
PATIENTS TREATMENT REGIMEN(s)
% never-
smokers
% EGFR 
mutant, 
intercalated 
arm only
ORR (%) MEDIAN PFS (months)
MEDIAN OS
(months)
Mok 2009 
(FASTACT) 26 
Randomized 
Phase 2
154 All histologies, 
previously untreated
Arm A (76 pts): 
Gem, d 1 & 8
Cis or Carbo, day 1
Erlotinib, d 15-28
Cycle q 4 weeks
Arm B (78 pts): 
as above, placebo 
instead of Erlotinib
34% 28% Arm A: 35.5%
Arm B: 24.4%
P = 0.12
Arm A: 6.9 m
Arm B: 5.5 m
P = 0.002
Arm A: 17.3 m
Arm B: 17.7 m
P: ns
52 As above, 
neversmokers
Arm A (24 pts)
Arm B (28 pts)
Treatment as above
100% 49% Arm A:  45.8%
Arm B: 32.1%
P: not 
reported
Arm A: 11.1 m 
Arm B: 6.4 m
P = 0.002
Not reached
Hirsch 2011 27 Randomized 
Phase 2
143 Positive for EGFR 
protein expression 
and/or with high 
EGFR gene copy 
number, previously 
untreated
Arm A (71 pts): 
Pacli d 1
Carbo d 1
Erlotinib d 2 - 15 
Cycle q 3 weeks
Arm B (72 pts): 
Erlotinib
28% 10% Arm A: 22.4%
Arm B: 11.6%
P = ns
Arm A: 4.6 m
Arm B: 2.7 m
P = ns
Arm A: 11.4 m
Arm B: 16.7 m
P = ns
Aerts 2012 
(NVALT 10) 28
Randomized 
Phase 2
231 All histologies
Progression after 
platin-based 
chemotherapy
Arm A (115 pts):
Erlotinib 
Arm B (116 pts):
Doce or Pem, d 1
Erlotinib, d 2 – 16
Cycle q 3 weeks
7% 4% Arm A: 7%
Arm B: 13%
P = 0.03
Arm A: 4.9 m
Arm B: 6.1 m
P = 0.11
Arm A:  5.5 m
Arm B: 7.8 m
P = 0.01
Lee 2013 29
 
Randomized 
Phase 2
240 Non-squamous, 
never-smokers, 
Progression after 1st 
line chemotherapy
Arm A (78 pts):
Pem d 1
Erlotinib d 2 – 14,Cycle 
q 3 weeks
Arm B (82 pts):
Erlotinib continuously
Arm C (80 pts):
Pem d 1,Cycle  q 3 
weeks
100% 56% Arm A: 44.7%
Arm B: 29.3%
Arm C: 10.0%
P = 0.001
Arm A: 7.4 m
Arm B: 3.8 m
Arm C: 4.4 m
P = 0.003
Arm A: 20.5 m
Arm B: 22.8  m
Arm C:  17.7 
m
P = 0.19
Wu Y-L 2013
(FASTACT 2) 30
 
 
Randomized 
Phase 3
451 All histologies, 
previously untreated
Arm A (226 pts): 
Gem, d 1 & 8
Cis or Carbo, d 1
Erlotinib, d 15-28
Cycle q 4 weeks
Arm B (225 pts): 
as above, placebo 
instead of Erlotinib
49% 39% Arm A: 44%
Arm B: 16%
P < 0.0001
Arm A:  7.6 m
Arm B: 6.0 m
P < 0.0001
Arm A: 18.3 m
Arm B: 15.2 m
P = 0.04
97 As above, subgroup 
with activating EGFR 
mutations
Arm A (49 pts):
Arm B (48 pts):
Treatment as above
Not  
separately 
reported
100% Arm A: 84%
Arm B: 15%
P < 0.0001
Arm A: 16.8 m
Arm B: 6.9 m
P < 0.0001
Arm A: 31.4 m
Arm B: 20.6 m
P = 0.009
Auliac 2014 31
 
Randomised 
Phase 2
147 EGFR wild-type or 
unknown
Progression after 1st 
line chemotherapy
Arm A (73 pts): 
Doce, d 1
Erlotinib, d 2 – 16 
Cycle q 3 weeks
Arm B (74 pts):
Doce, d 1
7.5% 4% Arm A: 4.4%
Arm B: 1.4%
P = ns
Arm A: 2.2 m
Arm B: 2.5 m
P = ns
Arm A:  6.5 m
Arm B: 8.3 m
P = ns
Karavasilis 
2014 32
Randomized 
Phase 2
50 All histologies
Previously untreated
Arm A (25 pts): 
Doce, d 1
Erlotinib, d 9 – 20 
Arm B (25 pts):
Doce, d 1
Erlotinib, d 3 – 14 
Cycle q 3 weeks
10% 11% Arm A: 24%
Arm B: 12%
Arm A: 2.9 m
Arm B: 4.2 m
Arm A: 9.9 m
Arm B: 10.8 m
Mok 2014 33 Randomized 
Phase 2
123 Unselected, 
progression after 
platin-based ChT
Arm A (63 pts):
Eribulin mesylate, d1
Erlotinib, d 2-16
Cycle q 3 weeks
Arm B (60 pts): 
Eribulin mesylate, d 1 
and 8
Erlotinib, d 15-28
Cycle q 4 weeks 
24% 28% Arm A: 13%
Arm B: 17%
P = ns
Arm A: 3.5 m
Arm B: 3.8 m
P = ns
Arm A: 7.6 m
Arm B: 8.5 m
P = ns
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REFERENCE TYPE OF TRIAL
# 
OF 
PTS
SELECTION OF 
PATIENTS TREATMENT REGIMEN(s)
% never-
smokers
% EGFR 
mutant, 
intercalated 
arm only
ORR (%) MEDIAN PFS (months)
MEDIAN OS
(months)
Yu 2014 34 Randomized 
Phase 2
117 Non-squamous, 
previously untreated
Arm A (58 pts): 
Pem, d 1
Cis or Carbo, d 1
Gefitinib, d 3 – 16
Cycle q 3 weeks
Arm B (57 pts):
As above, no Gefitinib
58% 40% Arm A:  50.0%
Arm B: 47.7%
P = ns
Arm A:  7.9 m
Arm B: 7.0 m
P = ns
Arm A:  25.4 
m
Arm B: 20.8 m
P = ns
32 As above, subgroup 
with activating EGFR 
mutations
Arm A: 14 pts
Arm B: 18 pts
Treatment as above
Not 
separately 
reported
100% Arm A: 76.9%
Arm B: 50.0%
P = 0.13
Arm A:  
Not reached
Arm B: 14.0 m
P = 0.017
Not reached
Choi 2015 35 Randomized 
Phase 2
90 NSCLC, EGFR wild.
type or unknown, 
PS 0 – 2, previously 
untreated
Arm A (44 pts): 
Pem, d 1
Carbo, d 1
Gefitinib, d 2 – 15
Cycle q 3 weeks x 4 
Maintenance Gefitinib
Arm B (46 pts):
As Arm A, no Gefitinib
10% 10% Arm A: 41.9%
Arm B: 39.5%
P = ns
Arm A:  4.1 m
Arm B: 4.1 m
P = ns
Arm A: 9.3 m
Arm B: 10.5 m
P = ns
Juan 2015 36 Randomized 
Phase 2
68 All histologies
Progression after 
platin-based 
chemotherapy
Arm A (33 pts): 
Doce q 3 weeks
Erlotnib, d 2 – 16  
Arm B (35 pts):
Erlotinib continuously
6% 5% Arm A: 3%
Arm B: 9%
P = 0.19
Arm A: 3.0 m
Arm B: 2.1 m
P = 0.09
Arm A:  7.5 m
Arm B: 5.2 m
P = 0.19
Lu 2015 37 Randomized 
Phase 3
219 Adenocarcinoma, 
EGFR unknown, 
non-smokers, no 
progression after 2 
cycles of gem-carbo
Arm A (109 pts): 
Gem, d 1 and 8
Carbo, d 1
Gefitinib d 15-25 and 
maintenance
Cycle q 4 weeks x 4
Arm B (110 pts):
As above, no Gefitinib
100% 72% Not reported Arm A: 10 m
Arm B: 4.4 m
P = 0.001
Not reported
Michael 
2015 38
 
Randomized 
Phase 2
54 All histologies
PS 2 or elderly
Previously untreated
Arm A (28 pts): 
Gem d 1 and 8
Erlotinib days 15 – 28 
Cycle q 4 weeks
Arm B (26 pts):
Gem d1 and 8
Cycle q 4 weeks
15% 12% Arm A: 6%
Arm B: 23%
P: ns
Arm A: 2.5 m
Arm B: 1.9 m
P: ns
Arm A: 3.9 m
Arm B: 4.4 m
P: ns
Han 2016 39 Randomized 
Phase 2
121 Adenocarcinoma, 
EGFR mutant, 
previously untreated
Arm A (40 pts): 
Pem, d1 + 
maintenance
Carbo, d1 for ≤ 6 cycles
Gefitinib, d 5-21 + 
maintenance
Cycle q 4 weeks
Arm B (40 pts):
As above, no Gefitinib
Arm C (41 pts):
Gefitinib alone
Not 
reported
100% Arm A: 82.5%
Arm B: 32.5%
Arm C: 65.9%
P: 0.04
Arm A: 18.8 m
Arm B: 5.7 m
Arm C: 12.0 m
P: not 
reported
Not reached
Lara 2016 
(SWOG 
S0709) 40
Randomized 
Phase 2
59 PS 2, Proteomics: 
VeriStrat-good 
status, previously 
untreated
Arm A (33 pts): 
Erlotinib
Arm B (26 pts):
Pacli d 1
Carbo d 1
Erlotinib d 2 – 16 
Cycle q 3 weeks x 4
Maintenance Erlotinib
20% 20% Arm A: 6%
Arm B: 23%
P = 0.06
Arm A: 1.6 m
Arm B: 4.6 m
P = 0.06
Arm A: 6.0 m
Arm B: 11.0 m
P = 0.27
Li 2016 41
 
Randomized 
Phase 2
79 Predominantly non-
squamous
Progression after 1st 
line chemotherapy
Arm A (27 pts):
Pem d 1
Cycle q 3 weeks
Arm B (52 pts):
Pem d 1
Erlotinib d 2 – 17
Cycle q 3 weeks
Not 
reported
19% Arm A: 10%
Arm B: 29%
P = 0.17
Arm A:  2.9 m
Arm B: 4.7 m
P = 0.26
Arm A: 8.3 m
Arm B: 9.7 m
P = 0.28
Lee 2016 42 Randomized 
Phase 2
76 Adenocarcinoma, 
neversmokers, 
Previously untreated
Arm A (39 pts):
Pem d1
Carbo d 1
Gefitinib d 5 – 18 + 
maintenance
Cycle q 3 weeks x 
max 9
Arm B (37 pts):
As arm A, placebo 
instead of Gefitinib
At progression: Gefitinib 
for arm B
100% 42% Arm A: 79.5%
Arm B: 51.4%
P = 0.01
Arm A: 12.8 m
Arm B: 7.0 m
P = 0.009
Arm A: 29.2 m
Arm B: 20.4 m
P = 0.15
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REFERENCE TYPE OF TRIAL
# 
OF 
PTS
SELECTION OF 
PATIENTS TREATMENT REGIMEN(s)
% never-
smokers
% EGFR 
mutant, 
intercalated 
arm only
ORR (%) MEDIAN PFS (months)
MEDIAN OS
(months)
29 As above, EGFR 
mutant
Arm A: 15 pts
Arm B: 14 pts 
Treatment as above
100% 100 Arm A: 86.7%
Arm B: 42.9%
P = 0.01
Arm A: 13.3 m
Arm B: 7.8 m
P = 0.08
Arm A: 26.6 m
Arm B: 22.2 m
P = ns
37 As above, EGFR wt Arm A: 22 pts
Arm B: 15 pts
Treatment as above
100% 0 Arm A: 72.7%
Arm B: 57.1%
P = ns
Arm A: 6.6 m
Arm B: 6.6 m
P = 0.08
Arm A: 29.2 m
Arm B: 15.9 m
P = 0.09
Yoon 2016 43 Randomized 
Phase 2
87 Non-squamous
Progression after 1st 
line chemotherapy
Arm A (57 pts):
Pem d 1
Afatinib d 2 – 15
Arm B (30 pts):
Pem d 1
31% 31% Arm A: 31.8 %
Arm B: 13.3%
P = 0.074
Arm A: 5.7 m
Arm B: 2.9  m
P = 0.16
Arm A: 12.1 m
Arm B: 15.6  m
P = 0.245
Carbo = carboplatin; Cis = cisplatin; Doce = docetaxel; Gem = gemcitabine; ORR = overall response rate; OS = overall survival; Pacli = paclitaxel; PFS = progression-free survival; 
 Pem = pemetrexed; PTS = patient
Erlotinib and gefitinib were used in 17 and 9 tri-
als, respectively. In 2 trials, either erlotinib or gefi-
tinib was used, while afatinib was used in 1 trial. 
Among 18 randomized trials (Table 1), chemo-
therapy alone was the comparator arm in 10 trials. 
Four trials used TKI alone as the comparator, 2 tri-
als compared two different intercalated schedules, 
while 2 trials used 3-arm design with comparison 
among intercalated schedule, chemotherapy alone 
or TKIs alone. According to PFS as the most com-
mon parameter of efficacy, the intercalated sched-
ule was superior to the comparator in 12 trials, 
crossing the conventional margin of P < 0.05 in 7 
trials. No significant difference was seen in 4 other 
trials and in 2 trials comparing two different inter-
calated schedules of intercalated therapy. 
Basic data on single-arm Phase 2 trials are pre-
sented in Table 2.
Efficacy of intercalated treatment 
Figure 2 shows correlation between median PFS 
and proportion of patients with non-squamous 
histology (Panel A), proportion of never-smokers 
(Panel B) and proportion of EGFR mutant patients 
(Panel C).
As for tumor histology, there was a moderate 
correlation between proportion of non-squamous 
tumors and median PFS in the first-line setting (R = 
0.61, R2 = 0.38, p = 0.02). The slope of the regression 
line (0.23) suggests that a 10% increase in the pro-
portion of non-squamous tumors corresponds to a 
2.3-months improvement in median PFS in first-line. 
On the other hand, the correlation was very weak in 
the second-line setting (R = 0.09, R2 = 0.01, p = 0.77). 
As for smoking status, there was a moderate 
correlation between proportion of non-smokers 
and median PFS, both in the first-line and in the 
second-line setting (first-line: R = 0.55, R2 = 0.30, p 
= 0.04; second-line: R = 0.65, R2 = 0.42, p = 0.02). In 
detail, the slope of the regression line (0.09 for the 
first-line and 0.05 for the second-line) suggests that 
a 10% increase in the proportion of non-smokers 
corresponds to a 0.9-months improvement in me-
dian PFS in first-line, and to a 0.5-months improve-
ment in median PFS in second-line.
40 50 60 70 80 90 100
0
5
10
15
20
25
0 20 40 60 80 100
0
5
10
15
20
25
0 20 40 60 80 100
0
5
10
15
20
25
A B C
MEDIAN
PFS
(months)
Percentage of non-squamous tumors Percentage of non-smokers Percentage of EGFR mutant tumors
FIGURE 2. Correlation between median PFS and proportion of patients with non-squamous histology (A), proportion of never-smokers (B) and proportion 
of EGFR mutant patients (C). Black solid marks and black solid lines are for 1st line treatment; red hollow marks and red interrupted lines for 2nd line 
treatment. Bubble size corresponds to the number of patients in a trial. 
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As for EGFR mutational status, there was a 
strong correlation between proportion of EGFR 
mutation-positive tumors and median PFS, both 
in the first-line and in the second-line setting (first-
line: R = 0.91, R2 = 0.83, p < 0.0001; second-line: R = 
0.69, R2 = 0.48, p = 0.006). The slope of the regression 
line (0.16 for the first-line and 0.06 for the second-
line) suggests that a 10% increase in the proportion 
of EGFR mutation-positive tumors corresponds to 
a 1.6-months improvement in median PFS in first-
line, and to a 0.6-months improvement in median 
PFS in second-line. 
Six trials on treatment-naive patients with EGFR 
mutant disease reported excellent response rate of 
83.1% (range: 76.9% to 84.2%).30,34,39,42,52,54 Five of 
these trials presented data on median PFS ranging 
from 13.3 to 23.4 months (median PFS for all 5 tri-
als: 18.6 months). This figure does not include an 
TABLE 2. Single-arm Phase II trials on intercalated chemotherapy and TKIs for non-small cell lung cancer
REFERENCE
# 
OF 
PTS
SELECTION OF 
PATIENTS TREATMENT REGIMEN(s)
% never-
smokers % EGFR mutant ORR (%) MEDIAN PFS (months)
MEDIAN OS
(months)
Oshita 2010 44 16 Unselected, 
previously 
untreated
Pacli d 1
Irino d 1
Gefitinib d 8-14
Cycle q 3 weeks
Not reported 25% 43.8% Not reported 18.1 m
Sangha 
2011 45
39 All histologies
Progression 
after 1st line 
chemotherapy
Doce d 1 
Erlotinib days 2 – 16
Cycle q 3 weeks 
28% 19% 28.2% 4.1 m 18.2 m
Minami 
2013 46
27 Non-squamous
Progression 
after 1st line 
chemotherapy
Pem, d 1
Erlotinib, d 2 – 16
Cycle q 3 weeks
22% 4% 11.1% 2.8 m 15.8 m
Yoshimura 
2013 47
27 Activating EGFR 
mutations,
Progression after 
TKI
Pem, d 1
Erlotinib or Gefitinib, days 
2 – 16 
Cycle q 3 weeks
78% 100% 25.9% 7.0 m 11.4 m
Kim 2014 48 17 Non-squamous, 
EGFR wt, 
progression after 
1st line ChT
Pem d 1
Erlotinib d 2-15 
27% 0% 27.0% 2.5 m 6.7 m
Fang 2014 49 57 Unselected, 
progression after 
platin-based ChT
Gem, d 1 and 8
Cis, d 1-3
Gefitinib, d 10 - 24
Cycle q 4 weeks
37% 40% 11% 10 m 15.2  m
Yang 2014 50 29 Adenocarcinoma, 
non-smokers, 
EGFR unknown, 
previously 
untreated
Pacli, d1
Carbo, d1
Gefitinib, d 8 – 17 + 
maintenance
Cycle q 3 weeks
100% 73% 74.1% 16 m Not reached
Zwitter 2014 51 15 Adenocarcinoma, 
light/never 
smokers, EGFR 
wild-type or 
unknown
Previously 
untreated
Gem d 1 and 4
Cis d 2
Erlotinib d 5 – 15
Cycle q 3 weeks x 4 – 6
Maintenance Erlotinib
100% 5% 33% 6.0 m 7.6 m
Yoshimura 
2015 52
26 Activating EGFR 
mutations
Previously 
untreated
Pem d 1
Gefitinib d 2 – 16 
46% 100% 84.6% 18.0 m 32.0 m
Yu 2015 53 42 Mostly 
adenocarcinoma
Progression after 
response to TKI 
Pem, d 1 or Pem + 
Platin, d 1
TKI (Erlotinib or Gefitinib), 
d 6 – 21
Cycle q 3 weeks 
71% 61% 23.8% 8.0 m 11.0 m
Zwitter 2016
(ITAC 2) 54
38 Activating EGFR 
mutations
Previously 
untreated
Gem d 1 and 4
Cis d 2
Erlotinib d 5 – 15
Cycle q 3 weeks x 4 – 6
Maintenance Erlotinib
63% 100% 84.2% 23.4 m 38.3 m
 Carbo = carboplatin; Cis = cisplatin; Doce = docetaxel; Gem = gemcitabine; Irino = irinotecan; ORR = overall response rate; OS = overall survival; Pacli = paclitaxel; PFS = 
progression-free survival; Pem = pemetrexed; PTS = patient
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additional trial from this category which reported 
86% PFS at 15 months, with no data on median PFS 
due to relatively short follow-up.34 
Discussion
Most surveys and meta-analyses focus on the ques-
tion of efficacy and/or toxicity of a particular new 
treatment in comparison with the standard ap-
proach. This was also the case with intercalated 
treatment for advanced NSCLC. On the basis of 
published randomized trials, a recent meta-analy-
sis concluded that intercalated treatment is supe-
rior to the comparator arm.24 While this meta-anal-
ysis offered a valuable insight into an area which is 
not in the main stream of current clinical research, 
the question of efficacy of intercalated treatment is 
too complex to be answered by a simple compari-
son. 
A critical look at all published trials reveals 
great heterogeneity in eligibility criteria including 
treatment-naive patients or those in progression 
after first-line therapy. In addition, we see a whole 
spectrum of biologically divergent disease: all his-
tologic types or only non-squamous histology; ex-
clusively EGFR–mutant disease, only EGFR–wt tu-
mors or, in most trials, both groups. On such a het-
erogeneous basis and without considering the op-
timal standard therapy for a particular population 
of patients, the value of a new approach cannot be 
assessed. Is the intercalated treatment superior to 
chemotherapy alone for EGFR–wt patients or su-
perior to TKI alone for EGFR–mutant patients? To 
be more concrete: it comes as no surprise that in-
tercalated treatment was superior to chemotherapy 
alone for a population which included a substantial 
proportion of EGFR–mutant patients;26,29,30,34,37,39,42 
and superior to TKIs alone for a population of pre-
dominantly EGFR–wt patients.36,40 It is not the in-
tercalated approach, but inclusion of an effective 
drug into the schedule which may be responsible 
for the positive experience in these trials. We be-
lieve that on the basis of randomized clinical tri-
als published so far, the question of superiority of 
intercalated schedules over the standard treatment 
cannot be answered.
Our estimate on the proportion of EGFR mutant 
patients, as used in the analysis, includes a con-
siderable degree of uncertainty. Only half of trials 
(14/29) included information on the proportion of 
EGFR–mutant vs. EGFR–wt tumors for more than 
50% of patients. Other trials reported results of 
EGFR analysis for a minority of patients, or (in 8 
publications) no such information. We therefore 
made an estimate, based on histologic types of tu-
mors (available for 28/29 trials), on proportion of 
never-smokers (available for 27/29 trials) and on 
the country where a trial was performed, using ta-
bles from a recent meta-analysis.25 This approach 
led us to the best possible estimate, but the results 
should nevertheless be regarded as exploratory 
and tentative. In future, precise molecular diagnos-
tics should minimize these uncertainties. 
Our survey does not include analysis of toxic-
ity of different schedules of intercalated treatment. 
This aspect was clearly presented in a recent re-
view: apart from the expected skin toxicity and 
diarrhea, intercalated schedules do not present a 
disproportional burden to patients.24
Relation between selection criteria and effective-
ness of intercalated treatment is shown in Figure 2. 
On the basis of pooled data on median PFS from 
randomized and single-arm trials, it is clear that 
pre-treated patients are not good candidates for 
a treatment which includes a modality to which 
resistance has already developed. While the pro-
portion of patients with non-squamous histology 
and of never-smokers determine efficacy of inter-
calated treatment, EGFR mutations are clearly the 
strongest predictive factor for longer PFS. By far 
the greatest benefit was for treatment-naive pa-
tients with activating EGFR mutations. According 
to trials in which this group of patients was report-
ed separately, their median PFS after intercalated 
treatment ranged between 13.3 and 23.4 months; 
median PFS for the pooled data was 18.4 months. 
This figure is substantially above PFS of 9 to 13 
months, as reported for TKIs as monotherapy for 
EGFR–mutant NSCLC.26,55-58 Response rate was also 
very high: 83.1%, with a substantial proportion of 
complete remissions. Our survey is in accordance 
with a recent editorial and with a meta-analysis, 
which pointed to intercalated regimens as the most 
promising first-line treatment for EGFR– mutated 
NSCLC.59,60 
With the introduction of liquid biopsy from pe-
ripheral blood, the category of patients with un-
determined EGFR mutant status should be very 
small.61 In case this new technique is not avail-
able, previously untreated never-smokers with 
non-squamous histology for whom EGFR status 
cannot be determined should also be considered 
for trials testing the role of intercalated treatment. 
Depending on ethnicity, approximately half of 
them have EGFR mutant tumors, in which case ad-
dition of TKI to cytotoxic drugs would be clearly 
beneficial; the other half with EGFR negative tu-
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mors should benefit from cytotoxic drugs included 
in the intercalated schedule. 
In future trials of intercalated treatment, pem-
etrexed with platin appears as the preferred option 
for the cytotoxic component. Regarding the choice 
of TKI, virtually all current experience is limited to 
erlotinib and gefitinib. Still, in view of recent very 
favorable experience for patients who developed 
resistance mutations, osimertinib intercalated with 
chemotherapy deserves to be considered either in 
first-line setting or for patients in progression after 
first-generation TKIs.62 
In two recent phase II randomized trials, pa-
tients with treatment-naive advanced EGFR– mu-
tant NSCLC were treated with continuous gefi-
tinib in combination with chemotherapy. As the 
comparator arm, sequential gefitinib and chemo-
therapy or gefitinib alone were applied.63, 64 In both 
trials, patients on the combination with continuous 
gefitinib and chemotherapy experienced longer 
PFS. These reports support the advantage of com-
bined treatment with chemotherapy and TKIs and 
re-open the dilemma between their concomitant 
and intercalated application. Combination of TKIs 
with bevacizumab is another possibility which de-
serves further attention.65 
We are perfectly aware that the correlation we 
have reported between the proportion of patients 
with EGFR mutation positive tumor and the me-
dian PFS obtained with the intercalated treatment 
could be reasonably observed also with EGFR in-
hibitors alone. The only way to assess the real add-
ed value of intercalated treatment is a randomized 
trial with comparison to TKI alone and overall sur-
vival as the principal endpoint.
In conclusion, intercalated treatment with cy-
totoxic drugs and TKIs is a promising approach 
for patients with previously untreated advanced 
NSCLC with activating EGFR mutations, as well 
as for never-smokers with adenocarcinoma and 
undetermined EGFR status. For these patients, 
randomized trials with comparison to the optimal 
standard treatment, or possibly to a third arm with 
continuous application of TKIs in combination 
with chemotherapy should define the preferred 
treatment approach.
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